glucose, (beta-d)-isomer has been researched along with Disease Exacerbation in 76 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (5.26) | 18.2507 |
| 2000's | 6 (7.89) | 29.6817 |
| 2010's | 43 (56.58) | 24.3611 |
| 2020's | 23 (30.26) | 2.80 |
| Authors | Studies |
|---|---|
| Iguchi, D; Ito, Y; Maruyama, S; Mizuno, M; Okada, A; Okada, H; Sakata, F; Suzuki, Y | 1 |
| Ichinose, T; Nishikawa, M; Sadakane, K | 1 |
| Brown, BR; Clowers, JS; Lee, EJ; Rosenzweig, HL; Sakaguchi, S; Snow, PS; Vance, EE | 1 |
| Dimitrova, P; Gyurkovska, V; Ivanovska, N; Schwaeble, W; Stover, C | 1 |
| Guo, H; Li, F; Liu, Q; Lu, JY; Wang, HW | 1 |
| Pallister, I; Topley, N | 1 |
| Geeraedts, LM; Goris, RJ; Hendriks, T; Jansen, MJ; Lange, W; Verhofstad, AA | 1 |
| Dwenger, A; Grotz, M; Pape, HC; Remmers, D; Tscherne, H; Vaske, R; Wisner, D | 1 |
| Bridges, CD; Cone, JB; Ferrer, TJ; Palmer, HE; Robertson, RD; Wallace, BH; Webb, JW | 1 |
| de Man, BM; Goris, RJ; Hendriks, T; Jansen, MJ; van der Meer, JW | 1 |
| Jackson, RJ; Johnson, DD; Maxson, RT; Smith, SD; Thomas, R | 1 |
| Haluzik, M; Hüttl, M; Malinska, H; Markova, I; Miklankova, D; Poruba, M; Vaněčkova, I; Zapletalova, I | 1 |
| Abd El-Fattah, EE; Abd-Eldayem, MA; Abdelhamid, AM; Alqarni, M; Amin, NA; Batiha, GE; Eissa, H; El-Ahwany, E; Etman, MA; Gaafar, AGA; Kaddah, MMY; Obaidullah, AJ; Saber, S; Shahien, MA; Youssef, ME | 1 |
| Choi, SE; Han, SJ; Heo, YJ; Jeon, JY; Kang, Y; Kim, DJ; Kim, HJ; Lee, KW; Lee, N | 1 |
| Tahara, A; Takasu, T | 1 |
| Verma, S | 1 |
| Abhinand, CS; Athira, PA; Soumya, SJ; Sudhakaran, PR | 1 |
| Han, GQ; Jia, WQ; Ma, J; Pu, TY; Xu, RX; Yang, CY; Zhu, JW; Zou, MM | 1 |
| Birnbaum, Y; Chen, H; Nylander, S; Tran, D; Yang, HC; Ye, Y | 1 |
| Hayashi, I; Kaneto, H; Katakami, N; Kawashima, S; Kosugi, K; Kuribayashi, N; Maeda, K; Mita, T; Nakamura, T; Ohtoshi, K; Okada, Y; Osonoi, T; Ryomoto, K; Sato, Y; Shimomura, I; Shiraiwa, T; Sumitani, S; Taki, H; Torimoto, K; Tsugawa, M; Umayahara, Y; Watada, H; Yamamoto, T; Yasuda, T; Yokoyama, H; Yoshii, H | 1 |
| Chen, JN; Lu, M; Luo, HR; Tan, L; Wu, GS; Yang, ZL; Zhou, XG; Zhu, Q | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Carson, P; Choi, DJ; Chopra, V; Chuquiure, E; Cotton, D; Filippatos, G; Giannetti, N; Gonzalez Juanatey, JR; Jamal, W; Janssens, S; Januzzi, J; Kaul, S; Kimura, K; Merkely, B; Nicholls, SJ; Packer, M; Perrone, S; Pina, I; Pocock, SJ; Ponikowski, P; Sattar, N; Schnee, J; Senni, M; Seronde, MF; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Wanner, C; Zannad, F; Zeller, C; Zhang, J | 1 |
| Ai, S; Blažek, P; Brittenham, GM; Chen, D; Chen, YP; Cortez, LM; Daude, N; Deisenhofer, I; Dwivedi, G; Eskandari-Sedighi, G; Fegan, PG; Friedrich, L; Fu, B; Gotoh, M; Grebmer, C; Green, G; Habibi, A; Hadadi, M; Hattori, R; Hectors, SJ; Hegde, AR; Iwata, H; Jabłońska, J; Jafari, R; Kantenwein, V; Karami, S; Kato, M; Kawanishi, H; Kluska, M; Koehne de González, AK; Kolb, C; Kulkarni, VI; Lan, NSR; Lan, X; Lennerz, C; Li, C; Li, Q; Li, X; Li, Y; Lim, MA; Lin, CH; Lin, XJ; Liu, R; Manne, ASN; Murase, Y; Mutalik, S; O'Connor, M; Pranata, R; Prince, MR; Rankin, JM; Rao, RR; Raut, SY; Reents, T; Sassa, N; Schaarschmidt, C; Seko, S; Shi, W; Shmeit, K; Sim, V; Spincemaille, P; Sun, G; Sun, J; Tsuzuki, T; Varmira, K; von Olshausen, G; Walker, MJ; Wang, Y; Wang, Z; Waterhouse, GIN; Weigand, S; Westaway, D; Xu, XM; Yang, J; Yeap, BB; Yi, X; Zhang, J; Zhang, M; Zhang, Y; Zheng, J; Zhou, M | 1 |
| Aaron, M; Collins, SP; Cox, ZL; Davidson, BT; Fowler, M; Hernandez, GA; Iii, ATM; Jenkins, CA; Jr, FEH; Kampe, C; Lindenfeld, J; Lindsell, CJ; Miller, KF; Stubblefield, WB | 1 |
| Haynes, R; Judge, PK | 1 |
| Khunti, K | 1 |
| Ambery, P; Berwanger, O; Buenconsejo, J; Chopra, V; Esterline, R; Gasparyan, SB; Javaheri, A; Koch, GG; Kosiborod, M; Langkilde, AM; Martinez, F; Mukhtar, O; Oscarsson, J; Sjöström, CD; Verma, S | 1 |
| Kang, L; Liu, Y; Wu, M; Xu, B; Xu, J | 1 |
| Bengtsson, O; Berg, DD; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Murphy, SA; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S | 1 |
| Larmour, K; Levin, A | 1 |
| Bengtsson, O; Butt, JH; Diez, M; Docherty, KF; Jhund, PS; Katova, T; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Ljungman, CEA; Martinez, FA; McMurray, JJV; O'Meara, E; Ogunniyi, MO; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD | 1 |
| Anastasiou, G; Hatziagelaki, E; Liberopoulos, E | 1 |
| Enomoto, A; Fujishiro, M; Ishigami, M; Ito, A; Itoh, M; Ochi, K; Ogawa, Y; Ogi, T; Ono, K; Sawada, M; Shiraki, Y; Suganami, T; Tanaka, M; Watanabe, A; Yoshioka, N | 1 |
| Ahangar, H; Arsang-Jang, S; Dadashi, M; Fathi, M; Ghaffari, S; Ghanbari, S; Gohari, S; Ismail-Beigi, F; Khodabandehloo, H; Muhammadi, MJ; Reshadmanesh, T | 1 |
| Martens, P; Mullens, W; Verbrugge, FH | 1 |
| de Zeeuw, D; Heerspink, HJL; Laverman, GD; Petrykiv, S | 1 |
| Toto, RD | 1 |
| Brown, AJM; Lang, C; McCrimmon, R; Struthers, A | 1 |
| Gao, H; Li, D; Wang, B; Wang, X; Yang, L; Zhang, L; Zhang, Q; Zhang, S; Zhang, Z | 1 |
| Calogero, E; Di Bello, V; Fabiani, I; Natali, A; Nesti, L | 1 |
| Chang, WX; Kumagai, T; Shibata, S; Tamura, Y; Uchida, S | 1 |
| Cui, Y; Han, L; He, Q; Jin, M; Liu, K; Zhang, S | 1 |
| Chen, C; Gan, L; Li, X; Luo, H; Zhou, Q; Zhu, M | 1 |
| Cherney, DZI; Heerspink, HJL; Inzucchi, SE; Kosiborod, M | 1 |
| Bell, DSH; Goncalves, E | 1 |
| Chatsudthipong, V; Chattipakorn, N; Chueakula, N; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Thongnak, LO; Wanchai, K | 1 |
| Atkin, SL; Butler, AE; Katsiki, N; Sahebkar, A; Yaribeygi, H | 1 |
| Chen, J; Gao, W; Lin, J; Shao, Z; Wang, H; Wang, K; Wang, X; Wu, C; Xu, T; Yan, Y; Zhang, X; Zhang, Z | 1 |
| He, Y; Liao, P; Lin, Z; Luo, G; Sun, E; Yang, F; Zhai, Z; Zheng, J; Zhuang, J; Zhuang, L | 1 |
| Chang, Y; Jia, X; Wang, C; Wei, W; Wu, Y; Yang, X; Zhang, L; Zhao, Y | 1 |
| Mallamaci, F; Zoccali, C | 1 |
| Bhatt, DL; Bonaca, MP; Cahn, A; Fredriksson, M; Furtado, RHM; Gause-Nilsson, IAM; Kuder, J; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Nicolau, JC; Raz, I; Ruff, CT; Sabatine, MS; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| Cherney, DZI; Hantel, S; Inzucchi, SE; Koitka-Weber, A; Mayer, GJ; von Eynatten, M; Wanner, C; Weir, MR; Zinman, B | 1 |
| Briand, F; Galsgaard, ED; Nørgaard, SA; Sand, FW; Sulpice, T; Søndergaard, H; Sørensen, DB | 1 |
| Cobble, ME; Kluger, AY; Lee, AY; Lepor, NE; Lerma, EV; McCullough, PA; Rangaswami, J; Tecson, KM | 1 |
| Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Meininger, G; Usiskin, K; Wajs, E; Xi, L; Yale, JF; Yue, D | 1 |
| Vouyiouklis, M | 1 |
| Fukazawa, M; Hiramatsu, M; Honda, K; Kawabe, Y; Matsumoto, M; Suzuki, M; Suzuki, Y | 1 |
| Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J | 1 |
| Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Jiang, J; Law, G; Meininger, G; Nieto, J; Usiskin, K; Wajs, E; Yale, JF; Yue, D | 1 |
| Edenhofer, I; Kapoor, S; Mitchell, K; Riwanto, M; Rodriguez, D; Segerer, S; Wüthrich, RP | 1 |
| Delman, DM; Fabian, CJ; Kimler, BF; Petroff, BK; Yeh, H | 1 |
| Adkins, SE; Bokaie, BB; Shubrook, JH | 1 |
| Gilbert, RE; Kepecs, DM; Thai, K; Zhang, Y | 1 |
| Hayashizaki, Y; Takakura, S; Takasu, T; Toyoshi, T | 1 |
| Abdul Razak, AR; Bartha-Vári, JH; Boros, Z; Cai, S; Carlson, R; Chong, YS; Chua, SY; Dagis, A; Feng, X; Foo, VH; Gabrail, NY; Gerecitano, JF; Gluckman, P; Huber, S; Ikram, MK; Irimie, FD; Kauffman, M; Kim, R; Kwek, K; Landesman, Y; Lassen, U; Li, D; Li, Q; Liu, C; Ma, J; Mahipal, A; Mau-Soerensen, M; McCauley, D; Mirza, MR; Nademanee, A; Ngo, C; Paizs, C; Palmer, JM; Pizzari, T; Poppe, L; Rashal, T; Saint-Martin, JR; Saw, SM; Shacham, S; Shields, AF; Stayner, LA; Tan, CS; Thorborg, K; Toşa, MI; Tsai, NC; Unger, TJ; Verkicharla, PK; Vértessy, BG; Wang, S; Wang, Y; Weiser, D; Wollin, M; Wong, TY; Xu, L; Yuan, L; Yuan, S; Zhang, Y; Zheng, R | 1 |
| Gu, Y; Li, W; Ming, Y; Xiao, L; Zheng, Z | 1 |
| Ding, Y; Guo, Q; Kong, L; Li, W; Lu, N; Sun, Y; Wang, X; Zhao, L; Zhao, Y | 1 |
| Cao, T; Du, G; Tang, G; Tian, Z; Wang, Y; Yao, H; Zhou, L | 1 |
| Broedl, UC; Fitchett, D; Inzucchi, SE; Johansen, OE; Lachin, JM; Mattheus, M; von Eynatten, M; Wanner, C; Woerle, HJ; Zinman, B | 1 |
| Prasad, K | 1 |
| Hyun, PM; Kim, BS; Kim, KS; Kim, SH; Lee, SI; Lee, SK; Lim, JS; Maeng, PJ | 1 |
| Fan, YB; Li, HX; Liu, YZ; Wang, Z; Yi, ZC; Yin, Y; Zhuang, FY | 1 |
| Hasumura, M; Hirose, M; Imai, T; Onose, J; Ueda, M | 1 |
| Dowlati, A; Gerson, SL; Hoppel, CL; Ingalls, ST; Ivy, P; Li, X; Majka, S; Remick, SC; Sedransk, N; Spiro, T | 1 |
14 review(s) available for glucose, (beta-d)-isomer and Disease Exacerbation
| Article | Year |
|---|---|
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Diseases; Chronic Disease; Disease Models, Animal; Disease Progression; Drug Combinations; Glucosides; Heart Failure; Humans; Mice; Natriuretic Peptides; Neprilysin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Valsartan | 2021 |
SGLT2 inhibitors in people with and without T2DM.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Heart Failure; Hospitalization; Humans; Mortality; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept.
Topics: Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Comorbidity; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys.
Topics: Benzhydryl Compounds; Disease Progression; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Natriuresis; Sodium-Glucose Transporter 1 | 2017 |
SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Topics: Allopurinol; Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Progression; Enzyme Inhibitors; Febuxostat; Glucosides; Gout Suppressants; Humans; Hyperuricemia; Monosaccharide Transport Proteins; Nitriles; Oxidative Stress; Pyridines; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid; Xanthine Oxidase | 2018 |
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Hospitalization; Humans; Kidney; Protective Agents; Renal Elimination; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways.
Topics: Benzhydryl Compounds; Blood Pressure; Canagliflozin; Disease Progression; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid | 2018 |
Nonproteinuric progressive diabetic kidney disease.
Topics: Albuminuria; Benzhydryl Compounds; Diabetic Nephropathies; Disease Progression; Glucosides; Humans; Proteomics; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Humans; Kidney; Protective Factors; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Canagliflozin: Improving diabetes by making urine sweet.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Humans; Hypoglycemic Agents; Thiophenes; Treatment Outcome; Urinalysis | 2013 |
Empagliflozin in the treatment of type 2 diabetes: evidence to date.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Natural products in regression and slowing of progression of atherosclerosis.
Topics: Animals; Antioxidants; Atherosclerosis; Biological Products; Butylene Glycols; Disease Progression; Flax; Glucosides; Humans; Hypercholesterolemia; Lignans; Oxidative Stress; Phytotherapy; Vitamin E | 2010 |
19 trial(s) available for glucose, (beta-d)-isomer and Disease Exacerbation
| Article | Year |
|---|---|
Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.
Topics: Aged; Benzhydryl Compounds; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucosides; Humans; Japan; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Proportional Hazards Models; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Topics: Acute Disease; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Progression; Glucosides; Heart Failure; Hospital Mortality; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Hypotension; Hypovolemia; Insulin; Natriuresis; Natriuretic Peptide, Brain; Patient Readmission; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2021 |
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Topics: Atherosclerosis; Benzhydryl Compounds; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cause of Death; Comorbidity; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Glucosides; Heart Failure; Humans; Hypertension; Kidney Diseases; Mortality; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Respiratory Insufficiency; SARS-CoV-2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Disease Progression; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Numbers Needed To Treat; Proportional Hazards Models; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Ventricular Dysfunction, Left | 2021 |
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
Topics: Aged; Benzhydryl Compounds; Disease Progression; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2021 |
Study rationale and design of a study of EMPAgliflozin's effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucosides; Glycated Hemoglobin; Humans; Inflammation Mediators; Iran; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2021 |
Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.
Topics: Administration, Oral; Benzhydryl Compounds; Blood Pressure Monitoring, Ambulatory; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Progression; Double-Blind Method; Glucosides; Humans; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Magnetic Resonance Imaging; Proof of Concept Study; Prospective Studies; Research Design; Risk Factors; Scotland; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiomyopathies; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucosides; Humans; Hypoglycemic Agents; Italy; Male; Middle Aged; Research Design; Ventricular Dysfunction, Left | 2017 |
Acteoside relieves mesangial cell injury by regulating Th22 cell chemotaxis and proliferation in IgA nephropathy.
Topics: Adult; Biopsy; Cell Line; Cell Proliferation; Chemokine CCL20; Chemokine CCL22; Chemokine CCL27; Chemotaxis; Coculture Techniques; Disease Progression; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; Glucosides; Humans; Immunosuppressive Agents; Male; Mesangial Cells; Middle Aged; Phenols; Proteinuria; Rehmannia; T-Lymphocytes, Helper-Inducer; Transforming Growth Factor beta1; Treatment Outcome; Valsartan; Young Adult | 2018 |
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Topics: Aged; Benzhydryl Compounds; Brain Ischemia; Cause of Death; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Time Factors; Treatment Outcome | 2019 |
Analysis from the EMPA-REG OUTCOME
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Benzhydryl Compounds; Calcium Channel Blockers; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Diuretics; Female; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Male; Middle Aged; Protective Agents; Regional Blood Flow; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
Topics: Aged; Biomarkers; Blood Glucose; Body Weight; Canagliflozin; Comorbidity; Diabetes Mellitus, Type 2; Disease Progression; Diuresis; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Urinary Tract Infections | 2013 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2014 |
Topics: Active Transport, Cell Nucleus; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Benzhydryl Compounds; Benzylamines; Biopsy; Blood Glucose; Blood Transfusion; Cholesterol, LDL; Combined Modality Therapy; Cyclams; Diabetes Mellitus, Type 2; Disease Progression; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Glucosides; Glycated Hemoglobin; Granulocyte Colony-Stimulating Factor; Hamstring Muscles; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Hydrazines; Immunohistochemistry; Insulin-Secreting Cells; Leg; Male; Middle Aged; Muscle Strength; Neoplasms; Peripheral Blood Stem Cell Transplantation; Range of Motion, Articular; Recurrence; Remission Induction; Research Design; Reverse Transcriptase Polymerase Chain Reaction; Soccer; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2 Inhibitors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Triazoles; Young Adult | 2015 |
Clinical observation on the treatment of oral lichen planus with total glucosides of paeony capsule combined with corticosteroids.
Topics: Adrenal Cortex Hormones; Adult; Capsules; China; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Lichen Planus, Oral; Male; Middle Aged; Paeonia; Plant Extracts; Prospective Studies; Treatment Outcome | 2016 |
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney; Male; Microvessels; Middle Aged; Proportional Hazards Models; Risk Factors | 2016 |
Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antineoplastic Agents; Carbazoles; Cholangiocarcinoma; Disease Progression; Dose-Response Relationship, Drug; Female; Gallbladder Neoplasms; Glucosides; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia | 2001 |
44 other study(ies) available for glucose, (beta-d)-isomer and Disease Exacerbation
| Article | Year |
|---|---|
Anti-C5a complementary peptide mitigates zymosan-induced severe peritonitis with fibrotic encapsulation in rats pretreated with methylglyoxal.
Topics: Animals; Complement Activation; Complement C5a; Complement Inactivating Agents; Disease Models, Animal; Disease Progression; Male; Peritoneal Fibrosis; Peritoneum; Peritonitis; Pyruvaldehyde; Rats, Sprague-Dawley; Severity of Illness Index; Signal Transduction; Time Factors; Zymosan | 2018 |
Effects of co-exposure of lipopolysaccharide and β-glucan (Zymosan A) in exacerbating murine allergic asthma associated with Asian sand dust.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Disease Progression; Dust; Immunoglobulin E; Immunoglobulin G; Lipopolysaccharides; Lung; Male; Mice, Inbred BALB C; Sand; Zymosan | 2019 |
Investigation of the relationship between the onset of arthritis and uveitis in genetically predisposed SKG mice.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; beta-Glucans; Disease Models, Animal; Disease Progression; Genetic Predisposition to Disease; Humans; Mice, Inbred BALB C; Mice, Knockout; Mutation, Missense; Severity of Illness Index; T-Lymphocytes; Time Factors; Uveitis; ZAP-70 Protein-Tyrosine Kinase; Zymosan | 2015 |
The role of properdin in murine zymosan-induced arthritis.
Topics: Animals; Arthritis; Complement C5a; Cytokines; Disease Progression; Mice; Mice, Inbred C57BL; Mice, Knockout; Properdin; Signal Transduction; STAT1 Transcription Factor; Synovitis; Zymosan | 2010 |
Altered MARCH1 ubiquination-regulated dendritic cell immune functions during the early stage of zymosan-induced multiple organ dysfunction syndrome (MODS) in mice.
Topics: Animals; CD11c Antigen; Dendritic Cells; Disease Models, Animal; Disease Progression; Gene Expression; Histocompatibility Antigens Class II; Lymphocyte Activation; Male; Mice; Multiple Organ Failure; Proteasome Endopeptidase Complex; Proteolysis; RNA Interference; Spleen; T-Lymphocytes; Ubiquitin-Protein Ligases; Ubiquitination; Zymosan | 2013 |
Chemiluminescence: comparison of whole blood with isolated polymorphonuclear leukocytes after major trauma.
Topics: Case-Control Studies; Cell Separation; Disease Progression; Humans; Inflammation; Injury Severity Score; Luminescent Measurements; Macrophage-1 Antigen; Multiple Organ Failure; Multiple Trauma; NADP; Neutrophil Activation; Neutrophils; Patient Selection; Predictive Value of Tests; Reactive Oxygen Species; Respiratory Burst; Respiratory Distress Syndrome; Risk Factors; Statistics, Nonparametric; Tetradecanoylphorbol Acetate; Time Factors; Zymosan | 2004 |
Gradual development of organ damage in the murine zymosan-induced multiple organ dysfunction syndrome.
Topics: Animals; Disease Models, Animal; Disease Progression; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Organ Size; Survival Rate; Time Factors; Zymosan | 1997 |
Multiple organ failure (MOF) after severe trauma--a sheep model.
Topics: Albumins; Animals; Bronchoalveolar Lavage Fluid; Capillary Permeability; Disease Models, Animal; Disease Progression; Endotoxins; Female; Femur; Fracture Fixation, Intramedullary; Heart Function Tests; Least-Squares Analysis; Leukocyte Count; Liver; Lung; Multiple Organ Failure; Multiple Trauma; Sheep; Shock; Zymosan | 1998 |
Interleukin-10 reduces morbidity and mortality in murine multiple organ dysfunction syndrome (MODS).
Topics: Animals; Disease Models, Animal; Disease Progression; Interleukin-10; Male; Mice; Mice, Inbred ICR; Multiple Organ Failure; Specific Pathogen-Free Organisms; Survival Analysis; Zymosan | 1998 |
Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cytokines; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Expression Regulation; Hemorrhage; Humans; Hypothermia; Interleukin-10; Lipopolysaccharides; Liver; Lung; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Organ Size; Recombinant Proteins; Spleen; Tumor Necrosis Factor-alpha; Zymosan | 1999 |
A comparison of neonatal and adult multiorgan failure in a rat model.
Topics: Age Factors; Animals; Animals, Newborn; Disease Models, Animal; Disease Progression; Kidney; Liver; Lung; Male; Multiple Organ Failure; Organ Size; Rats; Rats, Sprague-Dawley; Spleen; Surgical Procedures, Operative; Zymosan | 2000 |
In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia.
Topics: Animals; Benzhydryl Compounds; Cytochrome P-450 Enzyme System; Disease Models, Animal; Disease Progression; Glucosides; Hyperglycemia; Hyperlipoproteinemia Type IV; Inflammation Mediators; Insulin Resistance; Lipid Metabolism; Liver; Male; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Prediabetic State; Rats; Rats, Mutant Strains; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application.
Topics: Animals; Apoptosis; Autophagy; Benzhydryl Compounds; Carcinoma, Hepatocellular; Disease Progression; Glucosides; Hypoglycemic Agents; Liver Neoplasms; MAP Kinase Kinase Kinases; Metformin; Mice; Neovascularization, Pathologic; NF-kappa B; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease.
Topics: Amino Acids; Animals; Benzhydryl Compounds; Choline; Cytokines; Diet, High-Fat; Disease Models, Animal; Disease Progression; Glucosides; Inflammation; Inflammation Mediators; JNK Mitogen-Activated Protein Kinases; Liver; Macrophage Activation; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Phosphorylation; Piperidones; Protective Agents; Pyrimidines | 2022 |
SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Progression; Drug Therapy, Combination; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rodentia; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction.
Topics: Benzhydryl Compounds; Disease Progression; Glucosides; Heart Failure; Humans; Incidence; Randomized Controlled Trials as Topic; Recovery of Function; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2020 |
Multiple Targets Directed Multiple Ligands: An In Silico and In Vitro Approach to Evaluating the Effect of Triphala on Angiogenesis.
Topics: Angiogenesis Inhibitors; Benzopyrans; Cell Movement; Computer Simulation; Disease Progression; Enzyme-Linked Immunosorbent Assay; Glucosides; Human Umbilical Vein Endothelial Cells; Humans; Hydrolyzable Tannins; Ligands; Medicine, Ayurvedic; Molecular Docking Simulation; Neoplasms; Neovascularization, Pathologic; Plant Extracts; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Verbascoside inhibits progression of glioblastoma cells by promoting Let-7g-5p and down-regulating HMGA2 via Wnt/beta-catenin signalling blockade.
Topics: Animals; Apoptosis; Autophagy; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Disease Progression; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioblastoma; Glucosides; HMGA2 Protein; Humans; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Phenols; Protein Kinase C; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2020 |
Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
Topics: AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Disease Progression; Enzyme Activation; Fibrosis; Glucosides; Inflammasomes; Male; Mechanistic Target of Rapamycin Complex 2; Mice, Inbred C57BL; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Purinergic P2Y Receptor Antagonists; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ticagrelor; TOR Serine-Threonine Kinases; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Secoisolariciresinol Diglucoside Delays the Progression of Aging-Related Diseases and Extends the Lifespan of
Topics: Aging; Animals; Butylene Glycols; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Disease Progression; Forkhead Transcription Factors; Glucosides; Longevity; Oxidative Stress; Transcription Factors | 2020 |
Topics: Acute Coronary Syndrome; Adolescent; Adsorption; Adult; Aged; Animals; Aspergillus; Aspergillus oryzae; Benzhydryl Compounds; Biocatalysis; Biological Availability; Biomarkers; Biomass; Brain; Brain Injuries, Traumatic; Cadmium; Calorimetry, Differential Scanning; Carbon; Carcinoma, Transitional Cell; Catalysis; Cell Death; Cells, Immobilized; Child; Child, Preschool; China; Chitosan; Creatine Kinase, MB Form; Cyclodextrins; Defibrillators, Implantable; Dendritic Spines; Diabetes Mellitus, Type 2; Diastole; Directed Molecular Evolution; Disease Models, Animal; Disease Progression; Down-Regulation; Electric Countershock; Electrolytes; Electrophoresis, Polyacrylamide Gel; Endopeptidase K; Environmental Monitoring; Esterification; Esters; Feasibility Studies; Female; Fruit; Gene Library; Glial Fibrillary Acidic Protein; Glucosides; Hippocampus; Humans; Hydrogen-Ion Concentration; Hydrolysis; Infant; Infant, Newborn; Inflammation; Ions; Kinetics; Lipase; Liver Cirrhosis; Logistic Models; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malus; Maze Learning; Melatonin; Mercury; Mice; Mice, Inbred C57BL; Middle Aged; Mining; Molecular Docking Simulation; Molecular Weight; Molybdenum; Motor Cortex; Mutagenesis, Site-Directed; Mutation; Neoplasm Recurrence, Local; Nephrectomy; Nephroureterectomy; Neurons; Oxidative Stress; Patient Discharge; Proof of Concept Study; Propionates; Prospective Studies; Protein Engineering; Protein Structure, Quaternary; Protons; PrPC Proteins; PrPSc Proteins; Rats; Rats, Wistar; Recovery of Function; Registries; Retrospective Studies; Rivers; ROC Curve; Scrapie; Sodium-Glucose Transporter 2 Inhibitors; Solubility; Solvents; Spatial Memory; Stereoisomerism; Synapses; Temperature; Time Factors; Treatment Outcome; Troponin T; Urinary Bladder Neoplasms; Urinary Tract; Ventricular Function, Left; Ventricular Remodeling; Water; Water Pollutants, Chemical; Water Purification; X-Ray Diffraction; Young Adult; Zebrafish | 2021 |
Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity.
Topics: Animals; Atherosclerosis; Benzhydryl Compounds; Body Weight; Disease Progression; Glucosides; Inflammation; Lipids; Male; Mice; Neuropeptide Y; Norepinephrine; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System | 2021 |
Slowing Progression in CKD: DAPA CKD and Beyond.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Glucosides; Humans; Mineralocorticoid Receptor Antagonists; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cellular Senescence; Diabetes Mellitus, Experimental; Diet, Western; Disease Models, Animal; Disease Progression; Glucosides; Hepatocytes; Insulin; Liver; Liver Neoplasms; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Receptor, Melanocortin, Type 4; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Biomarkers; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Resistance; Female; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Kidney; Male; Membrane Transport Modulators; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency; Renin-Angiotensin System; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Protective role of liriodendrin in mice with dextran sulphate sodium-induced ulcerative colitis.
Topics: Animals; Anti-Inflammatory Agents; Colitis, Ulcerative; Cytokines; Dextran Sulfate; Disease Models, Animal; Disease Progression; Furans; Glucosides; Humans; Inflammation Mediators; Lipopolysaccharides; Macrophages; Male; Medicine, Chinese Traditional; Mice; Mice, Inbred BALB C; Peroxidase; RAW 264.7 Cells | 2017 |
Gastrodin Suppresses Pentylenetetrazole-Induced Seizures Progression by Modulating Oxidative Stress in Zebrafish.
Topics: Animals; Benzyl Alcohols; Convulsants; Disease Progression; Dose-Response Relationship, Drug; Glucosides; Oxidative Stress; Pentylenetetrazole; Reactive Oxygen Species; Seizures; Zebrafish | 2018 |
Increase in glycated haemoglobin concentrations after unwarranted prescription changes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Foot; Disease Progression; Dose-Response Relationship, Drug; Drug Substitution; Glucosides; Glycated Hemoglobin; Humans; Medical Futility; Practice Patterns, Physicians'; Retrospective Studies; Up-Regulation | 2018 |
Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Disease Progression; Endoplasmic Reticulum Stress; Glucosides; Inflammation; Kidney; Kidney Diseases; Male; Prediabetic State; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Parkin-mediated mitophagy as a potential therapeutic target for intervertebral disc degeneration.
Topics: Animals; Apoptosis; Autophagy; Cells, Cultured; Disease Models, Animal; Disease Progression; Gene Knockdown Techniques; Glucosides; Humans; Intervertebral Disc Degeneration; Male; Mitochondria; Mitophagy; Nucleus Pulposus; Phenols; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Transfection; Tumor Necrosis Factor-alpha; Ubiquitin-Protein Ligases; Up-Regulation | 2018 |
Polydatin effectively attenuates disease activity in lupus-prone mouse models by blocking ROS-mediated NET formation.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Disease Progression; Drugs, Chinese Herbal; Extracellular Traps; Female; Glucosides; Humans; Lupus Erythematosus, Systemic; Mice; Mice, Inbred BALB C; Reactive Oxygen Species; Stilbenes; Treatment Outcome | 2018 |
CP-25 combined with MTX/ LEF ameliorates the progression of adjuvant-induced arthritis by the inhibition on GRK2 translocation.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Cells, Cultured; Disease Progression; Drug Therapy, Combination; G-Protein-Coupled Receptor Kinase 2; Glucosides; Leflunomide; Male; Methotrexate; Monoterpenes; Random Allocation; Rats; Rats, Sprague-Dawley | 2019 |
Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; Diabetic Nephropathies; Diet, High-Protein; Disease Progression; Gene Expression Regulation; Glucosides; Kidney; Mice; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2019 |
Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans.
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Candida albicans; Candidiasis; Disease Progression; Female; Glucosides; Glycosuria; Kidney; Mice; Mice, Inbred C57BL; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urinary Tract Infections | 2014 |
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Kidney Failure, Chronic; Metformin; Microcirculation; Middle Aged; Myocardial Infarction; Nutrition Surveys; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Uric Acid | 2014 |
Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Biopsy; Body Weight; Cell Proliferation; Cyclic AMP; Disease Models, Animal; Disease Progression; Diuresis; Electrolytes; Epithelial Cells; Glucosides; Kidney; Kidney Function Tests; Male; Polycystic Kidney Diseases; Rats; Sodium-Glucose Transport Proteins; Ultrasonography | 2015 |
Effects of Flaxseed Lignan Secoisolariciresinol Diglucosideon Preneoplastic Biomarkers of Cancer Progression in a Model of Simultaneous Breast and Ovarian Cancer Development.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Butylene Glycols; Cell Adhesion; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Estrogen Receptor Modulators; Female; Flax; Glucosides; Ki-67 Antigen; Ovarian Neoplasms; Phytoestrogens; Precancerous Conditions; Rats; Rats, Inbred ACI; Seeds | 2015 |
Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Disease Progression; Fibrosis; Gene Expression; Glomerular Filtration Rate; Glucosides; Glycosuria; Humans; Hypertension, Renal; Hypoglycemic Agents; Kidney; Male; Nephrectomy; Proteinuria; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta1; Treatment Failure | 2016 |
Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Glucosides; Hyperglycemia; Hypoglycemic Agents; Male; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Disease Progression; Gene Expression Regulation, Neoplastic; Glucosides; Humans; Hydrolyzable Tannins; In Vitro Techniques; Mice; Mice, Nude; Receptors, Notch; Signal Transduction; Transcription Factor HES-1; Xenograft Model Antitumor Assays | 2016 |
Wogonoside prevents colitis-associated colorectal carcinogenesis and colon cancer progression in inflammation-related microenvironment via inhibiting NF-κB activation through PI3K/Akt pathway.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Colitis; Colorectal Neoplasms; Disease Progression; Flavanones; Glucosides; Humans; Inflammation; Mice; Mice, Inbred C57BL; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Tumor Microenvironment | 2016 |
Suppression of the onset and progression of collagen-induced arthritis by chebulagic acid screened from a natural product library.
Topics: Animals; Arthritis, Experimental; Benzopyrans; Biological Products; Cattle; CD4-Positive T-Lymphocytes; Collagen; Cytokines; Disease Progression; Dose-Response Relationship, Drug; Gene Expression; Glucosides; Granulocytes; Humans; Immunoglobulin G; Injections, Intraperitoneal; Jurkat Cells; Knee Joint; Mice; Mice, Inbred DBA; Receptors, Interleukin-2; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors | 2005 |
Tellimagrandin I enhances gap junctional communication and attenuates the tumor phenotype of human cervical carcinoma HeLa cells in vitro.
Topics: Antineoplastic Agents; Connexin 43; Disease Progression; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Fluoresceins; Gallic Acid; Gap Junctions; Gene Expression Regulation, Neoplastic; Glucosides; HeLa Cells; Humans; Hydrolyzable Tannins; In Vitro Techniques; Isoquinolines; Phenotype; Uterine Cervical Neoplasms | 2006 |
Lack of a significant effect of arctiin on development of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in ovariectomized Sprague-Dawley rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Carcinogens; Cell Transformation, Neoplastic; Disease Progression; Dose-Response Relationship, Drug; Female; Furans; Glucosides; Incidence; Mammary Neoplasms, Experimental; Ovariectomy; Random Allocation; Rats; Rats, Sprague-Dawley | 2007 |